ClinicalTrials.gg

Program

dezecapavir

Also written as “VH4011499”, “[14C]-VH4011499 (oral)” and “VH4011499 low dose Injection”.

In GlaxoSmithKline's pipeline, HIV capsid protein inhibitor. Its studies are mostly in HIV Infections, led by GlaxoSmithKline.

Furthest: phase 2, since Aug 23, 20238 company-led studies, 4 open or runningNext primary completion: Feb 18, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline84 open or runningphase 2since Aug 23, 2023May 23, 2022Feb 18, 2027phase 1 · NCT07934719
  • Named in GlaxoSmithKline’s own pipeline as VH4011499, phase 2, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 23, 2022First study: phase 1 study in HIV InfectionsFirst studyNCT05393271 · 73 enrolled · United States
  2. Aug 21, 2023Phase 1 study in HIV InfectionsNCT06012136 · 85 enrolled · United States
  3. Aug 23, 2023Phase 2 study in HIV InfectionsNCT06039579 · 44 enrolled · United States, Argentina, Canada and more
  4. Apr 11, 2024Phase 1 study in HIV InfectionsNCT06368986 · 60 enrolled · United States
  5. Dec 4, 2024Phase 1 study in HIV InfectionsNCT06724640 · 168 planned · United States
  6. Sep 6, 2026Phase 2 study in HIV InfectionsNCT07816250 · 200 planned
  7. Nov 6, 20262 phase 1 studies in HIV InfectionsNCT07934719, NCT07939594

Ahead

  1. Feb 18, 2027Primary completion: phase 1 study in HIV InfectionsNCT07934719
  2. Mar 12, 2027Primary completion: phase 1 study in HIV InfectionsNCT07939594
  3. Aug 16, 2028Primary completion: phase 1 study in HIV InfectionsNCT06724640
  4. Jun 10, 2032Primary completion: phase 2 study in HIV InfectionsNCT07816250

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“HIV capsid protein inhibitor”the company's pipeline, read by Claude · source

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07939594HIV Infections1Not yet recruitingMar 12, 202775
NCT07934719HIV Infections1Not yet recruitingFeb 18, 202718
NCT07816250HIV Infections2Not yet recruitingJun 10, 2032200
NCT06724640HIV Infections · United States1RecruitingAug 16, 2028168
NCT06368986HIV Infections · United States1CompletedOct 2, 202460
NCT06039579HIV Infections · United States, Argentina, Canada and more2CompletedJun 24, 202444
NCT06012136HIV Infections · United States1CompletedJun 9, 202685
NCT05393271HIV Infections · United States1CompletedApr 24, 202373

How it is read

Names in the registry

  • “VH4011499”, 6 entries
  • “[14C]-VH4011499 (oral)”, 1 entry
  • “VH4011499 low dose Injection”, 1 entry
  • “VH4011499 high dose Injection”, 1 entry
  • “VH4011499 Dose A”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.